Product Description
Benazepril is an angiotensin converting enzyme (ACE) inhibitor. It works by blocking a substance in the body that causes blood vessels to tighten. As a result, benazepril relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart. (Sourced from: https://www.google.com/search?client=safari&rls=en&q=benazepril&ie=UTF-8&oe=UTF-8)
Mechanisms of Action: ACE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Brazil | Bulgaria | Canada | Chile | China | Colombia | Dominican Republic | Egypt | European Medicines Agency | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hypertension | Acute Myeloid Leukemia
Known Adverse Events: Edema
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20131231 | P2 |
Active, not recruiting |
Hypertension |
None |